The effects of varenicline on methamphetamine self-administration and drug-primed reinstatement in female rats

Steven T. Pittenger, Scott T. Barrett, Shinnyi Chou, Rick A Bevins

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

While research has revealed heightened vulnerability to meth addiction in women, preclinical models rarely use female subjects when investigating meth seeking and relapse. The goal of the present study was to examine the effects of varenicline (Chantix®), a partial α4β2 and full α7 nicotinic acetylcholine receptor agonist, on meth self-administration and reinstatement in female rats. Sprague-Dawley rats were surgically implanted with an indwelling jugular catheter. Half of the rats were then trained to self-administer meth (0.056mg/kg/infusion) on a variable ratio 3 schedule of reinforcement; the other half earned intravenous saline during daily, 2h sessions. When responding stabilized, varenicline (0.0, 0.3, 1.0, 3.0mg/kg) was tested to determine how it altered meth taking. Varenicline was probed on 4 test days; each test separated by 2 standard self-administration sessions to assure responding remained stable. Following this testing was 15 extinction sessions. Twenty-four hours after the last extinction session were four consecutive days of meth-primed reinstatement. The same 4 doses of varenicline were examined to determine how it altered reinstatement triggered by 0.3mg/kg meth (IP). Rats readily self-administered meth. The higher doses of varenicline did not affect meth-taking in a specific fashion as active lever pressing was also slightly reduced in rats that has access to saline in the self-administration phase. Female rats displayed robust meth-primed reinstatement. Notably, the lower doses of varenicline increased meth-primed reinstatement. This amplified susceptibility to reinstatement (i.e., relapse) may be an impediment for the use of varenicline as a therapeutic to treat meth use disorder.

Original languageEnglish (US)
Pages (from-to)150-159
Number of pages10
JournalBehavioural Brain Research
Volume300
DOIs
StatePublished - Mar 1 2016

Fingerprint

Self Administration
Methamphetamine
Pharmaceutical Preparations
Reinforcement Schedule
Recurrence
Cholinergic Agonists
Indwelling Catheters
Varenicline
Nicotinic Receptors
Sprague Dawley Rats
Neck
Research

Keywords

  • Chantix®
  • Nicotinic acetylcholine receptor
  • Relapse
  • Stimulant abuse

ASJC Scopus subject areas

  • Behavioral Neuroscience

Cite this

The effects of varenicline on methamphetamine self-administration and drug-primed reinstatement in female rats. / Pittenger, Steven T.; Barrett, Scott T.; Chou, Shinnyi; Bevins, Rick A.

In: Behavioural Brain Research, Vol. 300, 01.03.2016, p. 150-159.

Research output: Contribution to journalArticle

@article{15f99a62fa0041acbd8d8fd334563e83,
title = "The effects of varenicline on methamphetamine self-administration and drug-primed reinstatement in female rats",
abstract = "While research has revealed heightened vulnerability to meth addiction in women, preclinical models rarely use female subjects when investigating meth seeking and relapse. The goal of the present study was to examine the effects of varenicline (Chantix{\circledR}), a partial α4β2 and full α7 nicotinic acetylcholine receptor agonist, on meth self-administration and reinstatement in female rats. Sprague-Dawley rats were surgically implanted with an indwelling jugular catheter. Half of the rats were then trained to self-administer meth (0.056mg/kg/infusion) on a variable ratio 3 schedule of reinforcement; the other half earned intravenous saline during daily, 2h sessions. When responding stabilized, varenicline (0.0, 0.3, 1.0, 3.0mg/kg) was tested to determine how it altered meth taking. Varenicline was probed on 4 test days; each test separated by 2 standard self-administration sessions to assure responding remained stable. Following this testing was 15 extinction sessions. Twenty-four hours after the last extinction session were four consecutive days of meth-primed reinstatement. The same 4 doses of varenicline were examined to determine how it altered reinstatement triggered by 0.3mg/kg meth (IP). Rats readily self-administered meth. The higher doses of varenicline did not affect meth-taking in a specific fashion as active lever pressing was also slightly reduced in rats that has access to saline in the self-administration phase. Female rats displayed robust meth-primed reinstatement. Notably, the lower doses of varenicline increased meth-primed reinstatement. This amplified susceptibility to reinstatement (i.e., relapse) may be an impediment for the use of varenicline as a therapeutic to treat meth use disorder.",
keywords = "Chantix{\circledR}, Nicotinic acetylcholine receptor, Relapse, Stimulant abuse",
author = "Pittenger, {Steven T.} and Barrett, {Scott T.} and Shinnyi Chou and Bevins, {Rick A}",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.bbr.2015.11.033",
language = "English (US)",
volume = "300",
pages = "150--159",
journal = "Behavioural Brain Research",
issn = "0166-4328",
publisher = "Elsevier",

}

TY - JOUR

T1 - The effects of varenicline on methamphetamine self-administration and drug-primed reinstatement in female rats

AU - Pittenger, Steven T.

AU - Barrett, Scott T.

AU - Chou, Shinnyi

AU - Bevins, Rick A

PY - 2016/3/1

Y1 - 2016/3/1

N2 - While research has revealed heightened vulnerability to meth addiction in women, preclinical models rarely use female subjects when investigating meth seeking and relapse. The goal of the present study was to examine the effects of varenicline (Chantix®), a partial α4β2 and full α7 nicotinic acetylcholine receptor agonist, on meth self-administration and reinstatement in female rats. Sprague-Dawley rats were surgically implanted with an indwelling jugular catheter. Half of the rats were then trained to self-administer meth (0.056mg/kg/infusion) on a variable ratio 3 schedule of reinforcement; the other half earned intravenous saline during daily, 2h sessions. When responding stabilized, varenicline (0.0, 0.3, 1.0, 3.0mg/kg) was tested to determine how it altered meth taking. Varenicline was probed on 4 test days; each test separated by 2 standard self-administration sessions to assure responding remained stable. Following this testing was 15 extinction sessions. Twenty-four hours after the last extinction session were four consecutive days of meth-primed reinstatement. The same 4 doses of varenicline were examined to determine how it altered reinstatement triggered by 0.3mg/kg meth (IP). Rats readily self-administered meth. The higher doses of varenicline did not affect meth-taking in a specific fashion as active lever pressing was also slightly reduced in rats that has access to saline in the self-administration phase. Female rats displayed robust meth-primed reinstatement. Notably, the lower doses of varenicline increased meth-primed reinstatement. This amplified susceptibility to reinstatement (i.e., relapse) may be an impediment for the use of varenicline as a therapeutic to treat meth use disorder.

AB - While research has revealed heightened vulnerability to meth addiction in women, preclinical models rarely use female subjects when investigating meth seeking and relapse. The goal of the present study was to examine the effects of varenicline (Chantix®), a partial α4β2 and full α7 nicotinic acetylcholine receptor agonist, on meth self-administration and reinstatement in female rats. Sprague-Dawley rats were surgically implanted with an indwelling jugular catheter. Half of the rats were then trained to self-administer meth (0.056mg/kg/infusion) on a variable ratio 3 schedule of reinforcement; the other half earned intravenous saline during daily, 2h sessions. When responding stabilized, varenicline (0.0, 0.3, 1.0, 3.0mg/kg) was tested to determine how it altered meth taking. Varenicline was probed on 4 test days; each test separated by 2 standard self-administration sessions to assure responding remained stable. Following this testing was 15 extinction sessions. Twenty-four hours after the last extinction session were four consecutive days of meth-primed reinstatement. The same 4 doses of varenicline were examined to determine how it altered reinstatement triggered by 0.3mg/kg meth (IP). Rats readily self-administered meth. The higher doses of varenicline did not affect meth-taking in a specific fashion as active lever pressing was also slightly reduced in rats that has access to saline in the self-administration phase. Female rats displayed robust meth-primed reinstatement. Notably, the lower doses of varenicline increased meth-primed reinstatement. This amplified susceptibility to reinstatement (i.e., relapse) may be an impediment for the use of varenicline as a therapeutic to treat meth use disorder.

KW - Chantix®

KW - Nicotinic acetylcholine receptor

KW - Relapse

KW - Stimulant abuse

UR - http://www.scopus.com/inward/record.url?scp=84951149378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951149378&partnerID=8YFLogxK

U2 - 10.1016/j.bbr.2015.11.033

DO - 10.1016/j.bbr.2015.11.033

M3 - Article

VL - 300

SP - 150

EP - 159

JO - Behavioural Brain Research

JF - Behavioural Brain Research

SN - 0166-4328

ER -